Systemic oncological therapy in breast cancer patients on dialysis

被引:0
作者
Khan, Salman [1 ]
Araji, Ghada [1 ]
Yetiskul, Ekrem [1 ]
Keesari, Praneeth Reddy [1 ]
Haddadin, Fadi [1 ]
Khamis, Zaid [1 ]
Chowdhry, Varun [1 ]
Niazi, Muhammad [2 ]
Afif, Sarah [3 ]
Dhar, Meekoo [2 ]
El-Sayegh, Suzanne [1 ]
机构
[1] Staten Isl Univ Hosp, Northwell Hlth, Dept Internal Med, 475 Seaview Ave, Staten Isl, NY 10305 USA
[2] Staten Isl Univ Hosp, Northwell Hlth, Dept Hematol & Oncol, Staten Isl, NY 10305 USA
[3] CUNY, Sch Med, Dept Internal Med, New York, NY 10031 USA
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 15卷 / 06期
关键词
Breast cancer; Systemic therapy; Renal replacement therapy; Dialysis; End-stage renal disease; Hormone therapy; Chemotherapy; TRASTUZUMAB EMTANSINE T-DM1; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; DOUBLE-BLIND; ADJUVANT CHEMOTHERAPY; HEMODIALYSIS-PATIENT; PERITONEAL-DIALYSIS; MEGESTROL-ACETATE; INCREASED RISK; PHARMACOKINETICS;
D O I
10.5306/wjco.v15.i6.730
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The advancement of renal replacement therapy has significantly enhanced the survival rates of patients with end-stage renal disease (ESRD) over time. However, this prolonged survival has also been associated with a higher likelihood of cancer diagnoses among these patients including breast cancer. Breast cancer treatment typically involves surgery, radiation, and systemic therapies, with approaches tailored to cancer type, stage, and patient preferences. However, renal replacement therapy complicates systemic therapy due to altered drug clearance and the necessity for dialysis sessions. This review emphasizes the need for optimized dosing and administration strategies for systemic breast cancer treatments in dialysis patients, aiming to ensure both efficacy and safety. Additionally, challenges in breast cancer screening and diagnosis in this population, including soft-tissue calcifications, are highlighted.
引用
收藏
页数:16
相关论文
共 114 条
  • [1] Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology
    Albini, Adriana
    Donatelli, Francesco
    Focaccetti, Chiara
    D'Elios, Mario Milco
    Noonan, Douglas M.
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2012, 7 (05) : 399 - 401
  • [2] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    Allison, Kimberly H.
    Hammond, M. Elizabeth H.
    Dowsett, Mitchell
    McKernin, Shannon E.
    Carey, Lisa A.
    Fitzgibbons, Patrick L.
    Hayes, Daniel F.
    Lakhani, Sunil R.
    Chavez-MacGregor, Mariana
    Perlmutter, Jane
    Perou, Charles M.
    Regan, Meredith M.
    Rimm, David L.
    Symmans, W. Fraser
    Torlakovic, Emina E.
    Varella, Leticia
    Viale, Giuseppe
    Weisberg, Tracey F.
    McShane, Lisa M.
    Wolff, Antonio C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) : 1346 - +
  • [3] Immunotherapy: Constructive Approach for Breast Cancer Treatment
    Anayyat, Umer
    Ahad, Faiza
    Muluh, Tobias Achu
    Zaidi, Syed Aqib Ali
    Usmani, Faiza
    Yang, Hua
    Li, Mengqing
    Hassan, Hammad Ali
    Wang, Xiaomei
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 925 - 951
  • [4] Breast calcifications in patients with end-stage renal disease
    Basu, Pallavi
    Leong, Lester Chee Hao
    Tan, Benjamin Yongcheng
    Tan, Benita Kiat Tee
    [J]. BREAST JOURNAL, 2019, 25 (03) : 515 - 516
  • [5] Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease
    Bednarek, Anna
    Mykala-Ciesla, Joanna
    Pogoda, Katarzyna
    Jagiello-Gruszfeld, Agnieszka
    Kunkiel, Michal
    Winder, Mateusz
    Chudek, Jerzy
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
  • [6] Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial
    Bines, J.
    Dienstmann, R.
    Obadia, R. M.
    Branco, L. G. P.
    Quintella, D. C.
    Castro, T. M.
    Camacho, P. G.
    Soares, F. A.
    Costa, M. E. F.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (04) : 831 - 836
  • [7] Breast Cancer Treatment (PDQ): Patient Version, 2002, PDQ Cancer Information Summaries Internet
  • [8] A real or apparent decrease in glomerular filtration rate in patients using olaparib?
    Bruin, M. A. C.
    Korse, C. M.
    van Wijnen, B.
    de Jong, V. M. T.
    Linn, S. C.
    van Triest, B.
    Rosing, H.
    Beijnen, J. H.
    van den Broek, D.
    Huitema, A. D. R.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (02) : 179 - 188
  • [9] Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
    Bruin, Maaike A. C.
    Sonke, Gabe S.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (12) : 1649 - 1675
  • [10] Cancer Incidence Among US Medicare ESRD Patients Receiving Hemodialysis, 1996-2009
    Butler, Anne M.
    Olshan, Andrew F.
    Kshirsagar, Abhijit V.
    Edwards, Jessie K.
    Nielsen, Matthew E.
    Wheeler, Stephanie B.
    Brookhart, M. Alan
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (05) : 763 - 772